[1] |
DING Gaozhong, LI Shanshan, SUN Lan, WEI Yun.
A case of hypereosinophilic syndrome successfully treated with dupilumab
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(8): 576-579.
|
[2] |
ZHANG Kun, CHEN Lixiu.
Bullous pemphigoid with positive pemphigus antibody in erythroderma: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(8): 606-608.
|
[3] |
YANG Zijing, PAN Meng, ZHAO Xiaoqing.
Dupilumab-induced immune drifting from atopic dermatitis to polymyalgia rheumatica: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(7): 508-511.
|
[4] |
WANG Tiyan, ZHOU Xiaohong.
Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(6): 413-416.
|
[5] |
ZHAO Dandan, ZHEN Li.
Analysis of the prognostic factors of bullous pemphigoid based on random forest model
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(5): 338-343.
|
[6] |
LIU Wenhong, YU Shaohua, KANG Ting, YUAN Yuan, ZHANG Renjuan, DU Hua, HE Chunfeng.
Bullous pemphigoid induced by multiple tumors was treated with PD-1 inhibitor: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(5): 364-366.
|
[7] |
ZHAO Qing, ZHANG Furen.
Minocycline induced facial and hand back skin hyperpigmentation: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(1): 43-44.
|
[8] |
CHEN Xue, TAN Cheng, SHAN Minjie, MIN Zhongsheng, JI Jin, CHEN Fang, LIU Qing, WU Hao, PAN Yongzheng.
Rituximab combined with glucocorticoid in the treatment of refractory bullous pemphigoid: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(3): 185-188.
|
[9] |
CHE Xuanlin, SU Juan, CHEN Mingliang.
Acquired hemophilia associated with bullous pemphigus: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(2): 110-111.
|
[10] |
LI Mengmeng, LI Jingyi, LIU Qingfeng, LIU Youqing, LI Wei.
Clinical efficacy and safety of dupilumab in the treatment of moderate and severe atopic dermatitis for 16 weeks
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(12): 849-852.
|
[11] |
JIANG Fei, ZHAO Qing, SUN Yonghu, ZHANG Zhaoxia, YANG Baoqi, YANG Qing, LIU Guoyan, SHI Zhongxiang, LIU Hong, ZHANG Furen.
Efficacy of dupilumab in 5 children with moderate-to-severe atopic dermatitis: a real-world study
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(11): 790-793.
|
[12] |
WANG Tingting, REN Hong, HU Wenlong, KUANG Weiwei.
Drug-indruced bullous pemphigoid induced: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(11): 814-816.
|
[13] |
XIE Zhuoting, LI Anni, ZHANG Peilian.
Update of drug-associated bullous pemphigoid
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(11): 833-836.
|
[14] |
BAI Lu, ZHU Caiyong.
Update of treatment for annular granuloma
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(11): 842-846.
|
[15] |
CHEN Xianxia, WU Yujuan, NIU Taoxiang, YU Bingqian, LUO Zhicheng.
Analysis of prognostic factors of bullous pemphigoid
[J]. China Journal of Leprosy and Skin Diseases, 2022, 38(10): 678-681.
|